Rapport Therapeutics, Inc. (RAPP)

Market Cap	1.21B
Revenue (ttm)	n/a
Net Income (ttm)	-88.31M
Shares Out	46.11M
EPS (ttm)	-2.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,361,344
Open	25.74
Previous Close	24.73
Day's Range	24.43 - 26.50
52-Week Range	6.43 - 42.27
Beta	n/a
Analysts	Strong Buy
Price Target	37.00 (+41.28%)
Earnings Date	Nov 6, 2025

About RAPP

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The com...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 7, 2024
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: RAPP
• Website: https://www.rapportrx.com

Financial Performance

Financial numbers in USD

Analyst Summary

According to 4 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $37.0, which is an increase of 41.28% from the latest price.

Price Target

$37.0

(41.28% upside)

Analyst Consensus: Strong Buy